

John K Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8798592/publications.pdf>

Version: 2024-02-01

106
papers

4,509
citations

156536

32
h-index

116156

66
g-index

106
all docs

106
docs citations

106
times ranked

5344
citing authors

#	ARTICLE	IF	CITATIONS
1	Symptoms of Women With High-Risk Early-Stage Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2022, 139, 157-162.	1.2	14
2	Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial. <i>Gynecologic Oncology</i> , 2022, 164, 278-287.	0.6	6
3	The association of obesity with type I uterine cancer – is this an oversimplification?. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 538-539.	0.7	9
4	Higher obesity and lower screening rates in Hispanic women and associated increased breast cancer in the United States.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10555-10555.	0.8	0
5	Human papillomavirus-associated cancers in Taiwan over the last 18 years: The potential impact of screening, vaccination, and smoking.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10574-10574.	0.8	0
6	The increasing incidence of alcohol-related cancers in young adults in the United States: Who is most at risk?. <i>Journal of Clinical Oncology</i> , 2022, 40, 10563-10563.	0.8	0
7	The disproportionate burden of cancer associated with social behaviors in young women in the United States.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10575-10575.	0.8	0
8	Increase in postmenopausal women with distant stage breast cancer in the United States over the last 18 years: Who is the most at risk?. <i>Journal of Clinical Oncology</i> , 2022, 40, 10537-10537.	0.8	0
9	Factors associated with the decreasing rate of oropharyngeal cancer in young adults in the United States.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10534-10534.	0.8	0
10	Characteristics of patients with neuroendocrine tumors in the United States: A study of 392,412 patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10572-10572.	0.8	0
11	Real-world trends of PARPi maintenance treatment uptake and progression-free survival (PFS) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the United States.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6580-6580.	0.8	1
12	Real-world use of PD-(L)1 immune checkpoint inhibitors (CPI) and post-CPI treatment patterns and outcomes in ovarian and endometrial cancer (2014-2021).. <i>Journal of Clinical Oncology</i> , 2022, 40, e18795-e18795.	0.8	0
13	Increase in incidence of advanced-stage breast cancer in Asian women versus White women: Can this be explained by the lower utilization of mammograms?. <i>Journal of Clinical Oncology</i> , 2022, 40, 10524-10524.	0.8	0
14	Trends in the Utilization of Palliative Care in Patients With Gynecologic Cancer Who Subsequently Died During Hospitalization. <i>American Journal of Hospice and Palliative Medicine</i> , 2021, 38, 138-146.	0.8	10
15	Publication of oral and video presentations from the Society of Gynecologic Oncology annual meeting over 11 years – What characteristics were important?. <i>Gynecologic Oncology Reports</i> , 2021, 35, 100688.	0.3	2
16	Real-world patterns and predictors of first-line maintenance use among patients with newly diagnosed advanced ovarian cancer: Is there an opportunity for change?. <i>Journal of Clinical Oncology</i> , 2021, 39, e18710-e18710.	0.8	0
17	Young patients with cancer related to modifiable behaviors in the United States: What can we learn from them?. <i>Journal of Clinical Oncology</i> , 2021, 39, 10560-10560.	0.8	0
18	Progress and trends in publication of oral and video presentations at the society of gynecologic oncology annual meeting from 2006 to 2016. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100758.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Racial disparities in high-risk uterine cancer histologic subtypes: A United States Cancer Statistics study. <i>Gynecologic Oncology</i> , 2021, 161, 470-476.	0.6	26
20	Invasive Paget's disease of the breast versus genitalia versus skin: What are the demographic and prognostic differences?. <i>Journal of Clinical Oncology</i> , 2021, 39, e17577-e17577.	0.8	0
21	Trends in modifiable behaviorally related cancers: Who is affected the most?. <i>Journal of Clinical Oncology</i> , 2021, 39, e13531-e13531.	0.8	0
22	HPV associated cancers in the United States over the last 15 years: Has screening or vaccination made any difference?. <i>Journal of Clinical Oncology</i> , 2021, 39, 107-107.	0.8	7
23	Trends of cancer associated with modifiable behavior in the U.S.: Is there a difference based on age, gender, or race?. <i>Journal of Clinical Oncology</i> , 2021, 39, 1542-1542.	0.8	0
24	Real-world progression-free survival among patients with newly diagnosed advanced ovarian cancer: Does maintenance therapy work?. <i>Journal of Clinical Oncology</i> , 2021, 39, e18707-e18707.	0.8	0
25	Prevalence of Oral Human Papillomavirus Infection by Number of Vaccine Doses Among US Adults. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab086.	1.4	3
26	The Healthcare Journey of Women With Advanced Gynecological Cancer From Diagnosis Through Terminal Illness: Qualitative Analysis of Progress Note Data. <i>American Journal of Hospice and Palliative Medicine</i> , 2021, , 104990912110642.	0.8	0
27	Does chemotherapy or radiation benefit surgical stage I uterine carcinosarcoma patients?. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 383-384.	0.7	5
28	Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit. <i>Gynecologic Oncology</i> , 2020, 159, 118-128.	0.6	8
29	Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance. <i>Gynecologic Oncology</i> , 2020, 159, 604-606.	0.6	3
30	Trends and survival outcomes of robotic, laparoscopic, and open surgery for stage II uterine cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1347-1355.	1.2	10
31	Relationship status and other demographic influences on survival in patients with ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1922-1927.	1.2	4
32	Human papillomavirus: The other invisible enemy. <i>Gynecologic Oncology</i> , 2020, 158, 254-255.	0.6	0
33	Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival. <i>Gynecologic Oncology</i> , 2020, 157, 67-77.	0.6	17
34	Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities. <i>Gynecologic Oncology</i> , 2020, 157, 121-130.	0.6	7
35	Uterine clear cell carcinoma risk in White versus non-White US subpopulations: does race matter?. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e81.	1.0	2
36	Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 717-726.	1.1	4

#	ARTICLE	IF	CITATIONS
37	Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 636-648.	5.1	366
38	SOLO1 versus SOLO2: Cost-effectiveness of olaparib as maintenance therapy for newly diagnosed and platinum-sensitive recurrent ovarian carcinoma among women with germline BRCA mutations (gBRCAmut).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5545-5545.	0.8	5
39	Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US. <i>Gynecologic Oncology</i> , 2018, 149, 318-323.	0.6	36
40	Disparities Associated With Inpatient Palliative Care Utilization by Patients With Metastatic Gynecologic Cancers: A Study of 3337 Women. <i>American Journal of Hospice and Palliative Medicine</i> , 2018, 35, 697-703.	0.8	22
41	Impact of age at diagnosis on racial disparities in endometrial cancer patients. <i>Gynecologic Oncology</i> , 2018, 149, 12-21.	0.6	28
42	Metastatic gynecologic malignancies: advances in treatment and management. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 521-533.	1.7	11
43	Cost-effectiveness of maintenance therapy in advanced ovarian cancer: Paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5508-5508.	0.8	4
44	Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology/Gynecologic Oncology Group (GOG) study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5517-5517.	0.8	23
45	Progress in record numbers of approved therapies for gynecologic cancers: The lack of upfront approval for newly diagnosed cases.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14551-e14551.	0.8	0
46	Characterization and predictors of long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5556-5556.	0.8	1
47	Differences in survival between Caucasians and Asians.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5570-5570.	0.8	0
48	Clear Cell Ovarian Cancer: Optimum Management and Prognosis Remain Hazy. <i>Gynecologic Oncology</i> , 2017, 147, 237-239.	0.6	3
49	Evaluating the cost-effectiveness of current FDA-approved PARP inhibitors for the treatment of recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5516-5516.	0.8	6
50	Clinical trial in progress: A phase 3 study of maintenance bi-shRNA-furin/GM-CSF-expressing autologous tumor cell vaccine in women with stage IIIb-IV high-grade epithelial ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5604-TPS5604.	0.8	4
51	Stage I ovarian immature teratomas: Is there a role for chemotherapy?. <i>Journal of Clinical Oncology</i> , 2017, 35, 5523-5523.	0.8	0
52	Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study. <i>BMC Medical Ethics</i> , 2016, 17, 63.	1.0	1
53	The economic impact of surgical care for morbidly obese endometrial cancer patients: a nationwide study. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 498.e1-498.e6.	0.7	13
54	Somatic Mosaic Mutations in <i>PPM1D</i> and <i>TP53</i> in the Blood of Women With Ovarian Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 370.	3.4	88

#	ARTICLE	IF	CITATIONS
55	Reply to F.M. Muggia. <i>Journal of Clinical Oncology</i> , 2016, 34, 882-883.	0.8	0
56	A Markov model to evaluate cost-effectiveness of the PARP inhibitor, olaparib, for fourth-line treatment of recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5563-5563.	0.8	3
57	The increase in FDA-approved novel cancer drugs over the last 5 years: What factors are involved?. <i>Journal of Clinical Oncology</i> , 2016, 34, e14111-e14111.	0.8	2
58	A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation â€” An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2015, 137, 386-391.	0.6	224
59	Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 188.e1-188.e6.	0.7	20
60	Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. <i>Gynecologic Oncology</i> , 2015, 139, 413-418.	0.6	18
61	Inverse Planned High-Dose-Rate Brachytherapy for Locoregionally Advanced Cervical Cancer: 4-Year Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1093-1100.	0.4	33
62	Foreign- vs US-born Asians and the association of type I uterine cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 43.e1-43.e6.	0.7	10
63	Ovarian Cancer Rates After Hysterectomy With and Without Salpingo-Oophorectomy. <i>Obstetrics and Gynecology</i> , 2014, 123, 65-72.	1.2	27
64	Applications for Oncologic Drugs: A Descriptive Analysis of the Oncologic Drugs Advisory Committee Reviews. <i>Oncologist</i> , 2014, 19, 299-304.	1.9	8
65	The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 132, 739-744.	0.6	122
66	Bevacizumab in Treatment of High-Risk Ovarian Cancerâ€”A Cost-Effectiveness Analysis. <i>Oncologist</i> , 2014, 19, 523-527.	1.9	33
67	Predictors of high symptom burden in gynecologic oncology outpatients: Who should be referred to outpatient palliative care?. <i>Gynecologic Oncology</i> , 2014, 132, 698-702.	0.6	44
68	MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 133, 568-574.	0.6	66
69	Factors associated with publication of plenary presentations at the Society of Gynecologic Oncologists annual meeting. <i>Gynecologic Oncology</i> , 2013, 128, 128-131.	0.6	7
70	In vitro chemosensitivity assay for patients with gynecologic sarcoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13078-e13078.	0.8	0
71	A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3058-3058.	0.8	3
72	Influence of Gynecologic Oncologists on the Survival of Patients With Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 832-838.	0.8	82

#	ARTICLE	IF	CITATIONS
73	The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2010, 116, 301-306.	0.6	118
74	Survival after recurrence in early-stage high-risk epithelial ovarian cancer: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2010, 116, 307-311.	0.6	45
75	Racial disparities in surgical treatment and survival of epithelial ovarian cancer in United States. <i>Journal of Surgical Oncology</i> , 2008, 97, 103-107.	0.8	82
76	The influence of conservative surgical practices for malignant ovarian germ cell tumors. <i>Journal of Surgical Oncology</i> , 2008, 98, 111-116.	0.8	79
77	Prognostic factors for high-risk early-stage epithelial ovarian cancer. <i>Cancer</i> , 2008, 112, 2202-2210.	2.0	131
78	Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 216.e1-216.e5.	0.7	24
79	Factors associated with the suboptimal treatment of women less than 55 years of age with early-stage ovarian cancer. <i>Gynecologic Oncology</i> , 2008, 108, 95-99.	0.6	14
80	Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. <i>Gynecologic Oncology</i> , 2008, 109, 370-376.	0.6	359
81	Analysis of Phase II Studies on Targeted Agents and Subsequent Phase III Trials: What Are the Predictors for Success?. <i>Journal of Clinical Oncology</i> , 2008, 26, 1511-1518.	0.8	58
82	Association of Lymphadenectomy and Survival in Stage I Ovarian Cancer Patients. <i>Obstetrics and Gynecology</i> , 2007, 109, 12-19.	1.2	131
83	Influence of the Gynecologic Oncologist on the Survival of Ovarian Cancer Patients. <i>Obstetrics and Gynecology</i> , 2007, 109, 1342-1350.	1.2	123
84	Role of complete lymphadenectomy in endometrioid uterine cancer. <i>Lancet Oncology</i> , The, 2007, 8, 831-841.	5.1	106
85	Impact of the Human Papilloma Vaccine on Cervical Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2975-2982.	0.8	58
86	Lymphadenectomy in endometrioid uterine cancer staging. <i>Cancer</i> , 2007, 109, 2454-2460.	2.0	85
87	Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: A multivariate analysis. <i>Gynecologic Oncology</i> , 2007, 104, 636-641.	0.6	162
88	The outcomes of 27,063 women with unstaged endometrioid uterine cancer. <i>Gynecologic Oncology</i> , 2007, 106, 282-288.	0.6	153
89	A novel technique for the enrichment of primary ovarian cancer cells. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, 507.e1-507.e5.	0.7	8
90	Enhanced Killing of Primary Ovarian Cancer by Retargeting Autologous Cytokine-Induced Killer Cells with Bispecific Antibodies: A Preclinical Study. <i>Clinical Cancer Research</i> , 2006, 12, 1859-1867.	3.2	114

#	ARTICLE	IF	CITATIONS
91	Patterns and Progress in Ovarian Cancer Over 14 Years. <i>Obstetrics and Gynecology</i> , 2006, 108, 521-528.	1.2	132
92	Improved Survival of Asians With Corpus Cancer Compared With Whites. <i>Obstetrics and Gynecology</i> , 2006, 107, 329-335.	1.2	17
93	Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2006, 103, 919-923.	0.6	18
94	Therapeutic role of lymph node resection in endometrioid corpus cancer. <i>Cancer</i> , 2006, 107, 1823-1830.	2.0	381
95	Suppression of Ovarian Cancer Cell Tumorigenicity and Evasion of Cisplatin Resistance Using a Truncated Epidermal Growth Factor Receptor in a Rat Model. <i>Cancer Research</i> , 2005, 65, 3243-3248.	0.4	29
96	Clinicopathologic features of six cases of primary cervical lymphoma. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 866-872.	0.7	51
97	Prognostic factors responsible for survival in sex cord stromal tumors of the ovaryâ€”A multivariate analysis. <i>Gynecologic Oncology</i> , 2005, 96, 204-209.	0.6	88
98	Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2005, 99, 20-25.	0.6	87
99	Patients With Malignancy Requiring Urgent Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 6794-6795.	0.8	22
100	Differences in Prognostic Molecular Markers between Women Over and Under 45 Years of Age with Advanced Ovarian Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 8538-8543.	3.2	25
101	Oral altretamine used as salvage therapy in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2004, 92, 368-371.	0.6	20
102	Conservative clitoral preservation surgery in the treatment of vulvar squamous cell carcinoma. <i>Gynecologic Oncology</i> , 2004, 95, 152-156.	0.6	12
103	Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. <i>Gynecologic Oncology</i> , 2003, 90, 181-185.	0.6	153
104	Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?. <i>Obstetrics and Gynecology</i> , 2003, 102, 156-161.	1.2	53
105	Borderline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome. <i>Journal of reproductive medicine, The</i> , 2003, 48, 756-60.	0.2	24
106	Prevention of femoral nerve injuries in gynecologic surgery. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 186, 1-7.	0.7	96